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Summary The combination of nicotinamide and carbogen breathing is awaiting clinical evaluation as a
strategy to overcome tumour hypoxia and thus enhance radiation response. We have continued our evaluation
of this approach in the murine SCCVII tumour with the aim of determining the importance of nicotinamide
dose and the pre-irradiation breathing time (PIBT) for carbogen. For carbogen breathing alone maximal
enhancement of radiation response was observed with PIBT's of between 5 and 30 min. When nicotinamide
(1,000 mg kg- ' IP) was administered 60 min prior to irradiation little or no variation in radiation response was
observed for all the PIBT's examined (5-90 min). Indeed at all PIBT's the cell survival obtained for the
carbogen nicotinamide and radiation combination was indistinguishable from that expected for a fully aerobic
response. For PIBT's of 15 and 60 min we examined the influence of nicotinamide doses between 50 and
1,000 mg kg- '. Significant radiosensitising effects were observed for all nicotinamide doses tested above
50 mg kg-'. Moreover for doses of 250 mg kg' and above the cell survival data was consistent with that
expected for a fully aerobic response. No additional benefit accrued from raising the nicotinamide dose above
250 mg kg-'. These results indicate that significant radiosensitisation may be expected even with clinically
achievable nicotinamide doses when it is combined with carbogen breathing. Furthermore, the use of
nicotinamide may reduce the critical importance of PIBT on the radiosensitisation observed with car-
bogen.
Several studies performed over the last 6 years provide
direct evidence that hypoxia in experimental rodent tumours
and human tumour xenografts can result from intermittent
non-perfusion of tumour blood vessels (Chaplin et al., 1986a,
1987; 1989; Jirtle, 1988; Minchinon et al., 1990; Trotter et al.,
1989; Chaplin & Trotter, 1991). If hypoxia in human
tumours results at least in part from such temporal changes
in microregional perfusion many of the approaches for im-
proving tumour oxygenation; e.g. breathing high-oxygen con-
tent gases with and without perfluorochemical emulsions
would prove ineffective at reoxygenating all of the
radiobiologically-resistant hypoxic cells. Indeed although
there is evidence that such approaches can produce im-
provements in the radiation response of tumours, overall, the
results in both experimental rodent tumours and in clinical
trials have been disappointing. (Teicher & Rose, 1984; Rock-
well, 1985, 1987; Song et al., 1985; Rockwell et al., 1986;
Rubin et al., 1979; Sasai et al., 1989).
One strategy to improve the effectiveness of such therapy
would be to combine it with a treatment which can prevent
the temporal microregional fluctuations in blood flow within
the tumour. Recent studies by us have identified nicotinamide
and pyrazinamide as agents which can reduce and/or
eliminate such intermittent changes in tumour blood flow
(Horsman et al., 1990; Chaplin et al., 1990a,b; Horsman,
1992).
Based on these findings we proposed (Chaplin et al.,
1990a; Horsman et al., 1990) and demonstrated (Chaplin et
al., 1991) that combining nicotinamide with carbogen and
perfluorochemical emulsions could provide large
enhancements of the response of the SCCVII tumour to
single doses of radiation. Subsequently in a series of elegant
experiments Kjellen et al. (1991) and Rojas (1991) have
shown large enhancements of tumour radiation response
when nicotinamide and carbogen are used in clinically
relevant multifraction treatments. All of these studies have
utilised nicotinamide at doses between 500-1,000 mg kg- I
which may not be achievable in a clinical setting. Recent,
preliminary reports have indicated that significant enhance-
ment of tumour radiation response can be achieved when
carbogen breathing is combined with nicotinamide doses as
low as 100 mg kg- (Rojas et al., 1992). Another factor
which can influence the efficacy of any therapeutic strategy
which utilises carbogen breathing is the effect of pre-
irradiation breathing time (PIBT) (Siemann et al., 1977). In
the present study we have continued our investigation of
nicotinamide and carbogen by evaluating the importance of
both nicotinamide dose and carbogen PIBT on the radiation
response of the murine SCCVII tumour.
Materials and methods
Mice and tumour
SCCVII tumours were obtained by injecting 106 tumour cells
subcutaneously over the sacral region of the back in 6-9
week old female C3H/He mice (Charles River Inc., Quebec,
Canada). Tumours were used in the size range 500-850 mg
for in vivo/in vitro assays, this size was attained 10-15 days
following implantation.
Drugs
Nicotinamide purchased from Sigma (St. Louis, Mo., USA)
was freshly prepared before each experiment. The drug was
dissolved in sterile phosphate-buffered saline (PBS) and
administered intraperitoneally (i.p.) in a volume of
0.5 ml 25 g-'.
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Irradiation procedure
Tumour localised irradiation was carried out without anaes-
thesia in a manner similar to that described previously (Shel-
don & Hill, 1977; Chaplin et al., 1983). Briefly, this involved
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placing the mice in individual perspex boxes which were lead
shielded. A portion of lead was cut out to expose the
posterior dorsum bearing the tumour to a horizontal i.e.
laterally directed X-ray beam (270 kv dose rate
2.9 Gymin-1). To ensure that the tumour was fully exposed
to the X-ray beam, a cardboard wedge was placed when
necessary under the hind feet. Four mice were mounted as
two pairs in front of two collimated appertures on a plate
which fitted on the head of the X-ray set. To ensure uniform
doses throughout the tumour volume, the mice were turned
through 1800 halfway through each irradiation.
Carbogen breathing
Animals were placed in their individual plexiglass/lead boxes
in the irradiation set-up. A plexiglass cover was then placed
over the set-up and clipped into place. The system was then
gassed with Carbogen (95% 02, 5% C02) for various times
prior to and during irradiation.
Preparation oftumour cell suspensions
The animals were sacrificed and tumours excised 18-20 h
after irradiation. Following excision, the tumours were
washed with PBS, chopped using crossed scalpels, and
weighed. The resulting fragments, after being washed with
PBS, were disaggregated by gentle agitation for 30 min with
an enzyme cocktail of trypsin (0.2%), DNase (0.05%) and
collagnease (0.05%) at 37°C. The resulting cell suspension
was filtered through polyester mesh (50ytm pore size), cent-
rifuged, and the cell pellet resuspended in medium. Cell
suspensions were routinely counted with the aid of a
haemocytometer enabling tumour cell yield to be ascertained.
The mean cell yields for tumours in this series of experiments
was 5.6 x 107 g ' of tissue.
Measurement ofcell survival
Tumour cell viability was assessed using the soft agar
clonogenic assay described previously (Courtenay, 1976).
Known numbers of tumour cells were pated into soft agar
and cultured in a water saturated atmosphere of 5% 02,
5% CO2 and 90% N2 for 14 days. Tumour colonies of more
than 50 cells were counted with the aid of a microscope. For
the present series of experiments, the plating efficiency for
untreated tumours ranged between 0.35 and 0.62. The effect
of treatment on cell survival was expressed as the fraction of
surviving cells per tumour, that is:
= S.F x cell yield/g treated
cell yield/g untreated
Results
Figure 1 shows the response of 500-850 mg tumours to
increasing X-ray doses. Also shown is the response of
SCCVII cells in vitro under aerobic conditions. It can be
observed that tumour cells irradiated in vivo are more resis-
tant to radiation doses > 10 Gy than those irradiated in
vitro. The resistance is due in large part to hypoxic cells as it
can be reduced or eliminated using hypoxic cell radiosen-
sitisers (Chaplin et al., 1986b). In order to study the effect of
a strategy which reduces tumour hypoxia we chose a radia-
tion dose of 14 Gy. Treating tumours with such a radiation
dose results in a large differential between the survival res-
ponse of fully aerobic cells and the radiobiologically hypoxic
tumour cells in the tumour but remains within the survival
range of our assay procedures. Figure 2 shows the effect of
pre-irradiation breathing time (PIBT) with carbogen on the
radiation response of SCCVII tumours. It can be seen that in
this tumour the optimum PIBT is between 5 and 30min. The
sensitising effect decreases with increasing time after 30 min
with little or no radiosensitisation being observed after
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Figure 1 The effect of X-ray dose on the survival of SCCVII
tumour cells (@) when irradiated as 500-850 mg tumours in vivo,
(0) when irradiated as single cells in culture. Results are the
mean (± s.e. of between 3 and 6 experiments).
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Figure 2 The effect of pre-irradiation breathing time with car-
bogen on tumour cell survival in 500-850 mg SCCVII tumours.
Mice were given of carbogen alone (0) carbogen plus
nicotinamide 1,000 mg kg-' administered i.p. 60 min prior to
irradiation (U). Results are mean (± s.e.) of 3 to 5 experiments.
Lower solid line indicates expected survival for a fully aerobic
response based on in vitro data.
90 min. Figure 2 also shows the effect on tumour cell survival
of combining nicotinamide (at a dose of 1,000 mg kg-'
administered 60 min prior to irradiation) with various PIBT's
of carbogen. It can be seen that for this combination a cell
survival response consistent with a fully aerobic radiation
response is observed at all PIBT's studied except 90 min.
The influence of nicotinamide dose on the response of the
SCCVII tumour to radiation when administered alone or
with carbogen is shown in Figure 3. The results indicate that
nicotinamide alone enhanced radiation response at all doses
above 50 mg kg-'. When combined with carbogen breathing,
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Figure 3 The effect of nicotinamide dose on the radiation re-
sponse of 500-850 mg kg-' SCCVII tumours, mice were given
nicotinamide alone 60 min prior to irradiation (0), nicotinamide
plus carbogen breathing PIBT -60 min (0), nicotinamide plus
carbogen breathing PIBT -15 min (U). Results are the mean
(± 1 s.e.) of 4 to 5 experiments. Lower solid line indicates
expected survival for a fully aerobic response based on in vitro
data.
nicotinamide enhanced the radiation response at all doses
tested above 50mgkg-'. This was the case for both PIBT's
examined; i.e. 15 min and 60 min. Maximal enhancement of
radiation response was observed when carbogen breathing
was combined with nicotinamide at a dose of 250 mg kg-' or
more. The level of survival achieved with this combination is
consistent with a fully aerobic response. No additional
enhancement was achieved by increasing the nicotinamide
dose from 250 to 1,000 mg kg-'. It can be also seen from
Figure 3 that significant sensitisation is observed with
nicotinamide at doses as low as 100 mg kg-' in combination
with carbogen. Figure 4 shows the radiation dose response of
the SCCVII tumour following treatments in which
nicotinamide at doses of 1,000, 250 and 100 mg kg-' IP was
combined with carbogen breathing (PIBT 60 min). It can be
seen that over the radiation dose range examined the res-
ponse for the combinations in which 1,000 and 250 mg kg-'
nicotinamide are used are indistinguishable from that
expected for an aerobic response. Significant enhancement of
radiation response is also observed in treatment combina-
tions in which 100 mg kg-' of nicotinamide is used.
Discussion
There is growing interest in the possible use of nicotinamide
and carbogen in clinical radiotherapy trials (Horsman, 1992;
Rojas et al., 1992). We have previously shown in the SCCVII
and KHT tumours that nicotinamide, when combined with
carbogen and a perfluorochemical emulsion, can enhance the
response to single doses of X-rays. Moreover evidence from
both histological and flow cytometric techniques indicated
that the mechanism responsible for this enhancement was
reduction in hypoxia resulting from both diffusion limitations
and from transient alterations in microregional perfusion of
the tumour. However, as indicated in the introduction most
of the studies with nicotinamide have been carried out at
doses of 500 mg kg-' and above which may not be
achievable in a clinical protocol. In the present study we have
extended our previous observations to investigate the effect
of nicotinamide dose and carbogen PIBT. Tumours in the
size range 500-850 mg were chosen because previous studies
have indicated that such tumours will exhibit perfusion
limited hypoxia. However, recent studies have shown that
similar results can be observed in smaller tumours (i.e.
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Figure 4 The effect on nicotinamide plus carbogen (PIBT -
60 min) on the radiation response of 500-850 mg SCCVII
tumours. Mice were given nicotinamide 1,000 mg kg-' (0),
nicotinamide 250 mg kg-' (0), nicotinamide 100 mg kg- ' (A).
The solid lines are those redrawn from Figure 1 for tumour
response in vivo and the aerobic in vitro response. Results are
mean (± I s.e.) of 4 to 5 experiments.
250-500 mg) (Chaplin et al. unpublished studies).
Our studies demonstrate that variations in radiation re-
sponse of the SCCVII are seen with carbogen PIBT, which is
consistent with previous reports in other tumours (Siemann
et al., 1977). However, no variation in such response for
PIBT between 5 and 60 min is observed if nicotinamide
(1,000 mg kg-1) is combined with carbogen. Indeed the re-
sponse observed in Figure 2 for this combination is consis-
tent with that for a fully aerobic response. If these studies are
applicable to human studies it would suggest that strict con-
trol of PIBT may not be necessary to achieve the therapeutic
benefit when nicotinamide is combined with carbogen.
The question as to what dose of nicotinamide will be
achievable in the clinic has not been answered as yet,
although doses of up to 6 g are clinically acceptable (Zack-
heim et al., 1981). Recent pharmacokinetic studies in humans
have now utilised nicotinamide doses of up to 6 g (Horsman,
1992; Stratford et al., 1992). The study by Horsman has
suggested that in the mouse, sensitisation is linked to peak
plasma levels. The human pharmacokinetic studies indicate
that 6 g of nicotinamide will produce a peak plasma level of
between 120-190 fg ml-' and that the same plasma level is
achieved in mice with a dose of 100-200 mg kg-' (Horsman,
1992). In our present study using the SCCVII tumour, a fully
aerobic radiation survival response is achieved using a
nicotinamide dose of 250 mg kg-' when combined with car-
bogen breathing. If nicotinamide operates by similar
mechanism in fractionated radiotherapy in human tumours
as it does in single radiation doses in mouse tumours and the
effect depends on peak plasma levels, then a dose of 8-9 g
given to humans in combination with carbogen could pro-
duce similar effects to those seen with 250 mg kg-'
nicotinamide plus carbogen in our murine system. It can be
seen from Figure 4 that a dose of nicotinamide as low as
100mgkg-' when combined with carbogen breathing pro-
duces a level of sensitisation equivalent to reoxygenating
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-- 80% of the hypoxic cells in this tumour and an equivalent
dose in humans can be achieved. Significant enhancements of
radiation/carbogen combinations by nicotinamide at doses as
low as 100 mg kg-' have also been indicated in a preliminary
report by Rojas et al. (1992) in the Carcinoma NT.
One other implication from the present study, when com-
pared to our previous report (Chaplin et al., 1991), is that
little or no benefit is achieved in the SCCVII tumour by the
adjuvant use of the perfluorochemical emulsion Fluosol DA
with the nicotinamide and carbogen combination i.e. similar
enhancements in tumour cell kill can be achieved in the
nicotinamide carbogen breathing combination in the presence
or absence of perfluorochemical emulsions. However it is
possible that such adjuvant treatment may prove beneficial in
other tumour types particularly if nicotinamide does not
facilitate the resumption of erythrocyte flow in some
vessels.
Several reservations have been raised regarding the use of
nicotinamide and carbogen in clinical radiotherapy (Brown,
1992). These were: (1) Could levels of nicotinamide required
to achieve radiosensitisation in mice be achieved in man? (2)
Could radiosensisation be achieved at radiation doses used in
clinical radiotherapy? (3) Could carbogen breathing improve
the oxygen tension within human tumours to the same degree
as it does in mouse tumours? (4) Is the occurrence of per-
fusion limited hypoxia and/or the ability of nicotinamide to
reduce it, a phenomenon only found in transplantable murine
tumours? The first three of these points have been addressed
to some extent in recent publications (Falk et al., 1992;
Horsman, 1992; Rojas et al., 1992). The last point cannot as
yet be definitively addressed since the techniques currently
available for quantitating perfusion limited hypoxia can not
be used in the clinic. However, there is no reason to believe
that non-perfusion of vessels does not contribute to the level
of radiobiological hypoxia in human tumours. A positive
outcome of clinical trials with nicotinamide and carbogen is
currently the only way of providing, albeit indirectly,
evidence for this.
In summary, the present studies have continued our inves-
tigation into the use of nicotinamide to improve radiation
response of tumours via a reduction in tumour hypoxia. The
results support our previous data and confirm that
nicotinamide when combined with breathing of high oxygen
content gasses can dramatically improve the tumours' radia-
tion response. Moreover this effect is seen at nicotinamide
doses which appear to be achievable in the clinic. Although
more work with such treatment strategies is warranted in-
cluding studies with spontaneous tumours, these results
together with other available data strongly suggest that
nicotinamide and carbogen should be evaluated as a treat-
ment to improve the response to radiotherapy in the clinic,
particularly in tumour sites where hypoxia is considered one
of the limiting factors.
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